Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

November 30, Top 20 Shareholders

201130_Top_Holders_Report

Categories: News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard December 1, 2020

Related posts

September 30, Top 20 Shareholders
October 1, 2021

August 31, Top 20 Shareholders
September 1, 2021

July 31, Top 20 Shareholders
August 1, 2021

June 30, Top 20 Shareholders
July 1, 2021

May 31, Top 20 Shareholders
June 1, 2021

April 30, Top 20 Shareholders
May 1, 2021

Recent Articles

October 1, Entitlement Options Issue Prospectus
October 1, 2021
October 1, Pro-Rata Non-Renounceable Entitlement Options Offer
October 1, 2021
October 1, Top 100 Shareholders
October 1, 2021
September 30, Top 20 Shareholders
October 1, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @PharmAust·

PharmAust doubles life expectancy of pet dogs with cancer, a major step towards commercialisation

https://stockhead.com.au/health/pharmaust-doubles-life-expectancy-of-pet-dogs-with-cancer-a-major-step-towards-commercialisation/

Reply on Twitter 1452404704596557826 Retweet on Twitter 14524047045965578261 Like on Twitter 14524047045965578268 Twitter 1452404704596557826

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions